MO3-3 Phase II Study of S-1+CDDP with Concurrent TRT Followed by Durvalumab for Unresectable LA-NSCLC in Japan (SAMURAI)
Annals of Oncology(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined